Instructions / Instruction for use: NolvadexI want this, give me price
Active substance Tamoxifen
ATX code L02BA01 Tamoxifen
Estrogens, gestagens; Their homologues and antagonists
Antineoplastic hormonal agents and hormone antagonists
Nosological classification (ICD-10)
C50 Malignant neoplasm of breast
Cancer of the nipple and areola of the breast, Breast carcinoma, The hormone-dependent form of recurrent breast cancer in women in menopause, Hormone-dependent breast cancer, Disseminated breast carcinoma, Disseminated Breast Cancer, Malignant breast cancer, Malignant neoplasm of breast, Contralateral breast cancer, Locally advanced or metastatic breast cancer,Locally-distributed breast cancer, Locally-recurring breast cancer, Metastatic breast carcinoma, Metastasis of breast tumors, Metastatic breast carcinoma, Inoperable breast carcinoma, Incompatible breast cancer, Breast cancer in women with metastases, Breast cancer in men with metastases, Breast Cancer, Breast cancer in men, Mammary cancer, Breast cancer with distant metastases, Breast cancer in postmenopausal women, Breast cancer hormone-dependent, Breast cancer with local metastases, Breast cancer with metastases, Breast cancer with regional metastases,Breast cancer with metastases, Common hormone-dependent forms of breast cancer, Common Breast Cancer, Recurrent Breast Cancer, Recurrence of breast tumors, Breast cancer, Estrogen-dependent breast cancer, Estrogen-Dependent Breast Cancer, Disseminated breast cancer with overexpression of HER2, Tumors of the mammary glands
Composition and form of release
1 tablet, coated, contains tamoxifen (in the form of citrate) 10 or 20 mg; In blistere 10 pcs., In a cardboard box 3 blisters.
Pharmacological action - antitumor, antiestrogenic.
Quickly absorbed, within 4-7 hours, the maximum concentration in the blood is created. The equilibrium concentration (300 ng / mg) is achieved with a daily dose of 40 mg for 4 weeks. 99% bound to albumin. Metabolised, excreted with feces, half-life for tamoxifen - 7 days, X-desmethyltamoxifen (main metabolite) - 14 days.
Tides, vaginal bleeding, endometrial hyperplasia, vulvar pruritus, dyspeptic disorders, dizziness, water retention in the body, hypercalcemia, thrombocytopenia, alopecia, uterine fibroids, leukopenia, thromboembolism.
Potentiates the effect of anticoagulants. When combined with cytotoxic agents, thromboembolic complications are possible.
Dosing and Administration
Inside, with breast cancer - 20-40 mg / day (for 1 or 2 reception).
In the dark place at a temperature of no higher than 30 ° C.
Keep out of the reach of children.
Do not use after the expiry date printed on the package.